Get the Stockscreener App
85.01
3.37%
2.77
After Hours:
84.57
-0.44
-0.52%
Tempus Ai Inc stock is traded at $85.01, with a volume of 8.73M.
It is up +3.37% in the last 24 hours and up +23.69% over the past month.
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
See More
Previous Close:
$82.24
Open:
$83.695
24h Volume:
8.73M
Relative Volume:
1.33
Market Cap:
$15.43B
Revenue:
$1.36B
Net Income/Loss:
$-302.91M
P/E Ratio:
-49.48
EPS:
-1.7182
Net Cash Flow:
$-219.93M
1W Performance:
+9.21%
1M Performance:
+23.69%
6M Performance:
+81.80%
1Y Performance:
+9.93%
1-Day Range:
$80.31
$85.46
1-Week Range:
$74.81
$85.46
52-Week Range:
$40.77
$104.32
Tempus Ai Inc Stock (TEM) Company Profile
Name
Tempus Ai Inc
Sector
Industry
Phone
800-976-5448
Address
600 WEST CHICAGO AVENUE, CHICAGO
Compare TEM vs VEEV, BTSG, TXG, HNGE
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TEM
Tempus Ai Inc
|
85.01 | 15.43B | 1.36B | -302.91M | -219.93M | -1.7182 |
VEEV
Veeva Systems Inc
|
280.68 | 45.44B | 3.32B | 941.65M | 1.64B | 5.6161 |
BTSG
Brightspring Health Services Inc
|
56.59 | 11.20B | 13.65B | 169.86M | 412.12M | 1.0758 |
TXG
10 X Genomics Inc
|
85.71 | 11.17B | 638.78M | -22.66M | 122.18M | -0.1744 |
HNGE
Hinge Health Inc
|
95.57 | 7.71B | 646.34M | -512.40M | 202.76M | -6.6871 |
Tempus Ai Inc Stock (TEM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-13-26 | Initiated | Jefferies | Underperform |
| Apr-13-26 | Upgrade | TD Cowen | Hold → Buy |
| Feb-19-26 | Initiated | Mizuho | Outperform |
| Feb-17-26 | Initiated | Robert W. Baird | Outperform |
| Dec-02-25 | Resumed | Morgan Stanley | Overweight |
| Oct-21-25 | Downgrade | TD Cowen | Buy → Hold |
| Oct-20-25 | Initiated | Canaccord Genuity | Buy |
| Sep-02-25 | Initiated | H.C. Wainwright | Buy |
| Apr-21-25 | Initiated | BTIG Research | Buy |
| Feb-25-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-12-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Feb-05-25 | Resumed | TD Cowen | Buy |
| Dec-13-24 | Initiated | Wolfe Research | Outperform |
| Dec-09-24 | Initiated | Guggenheim | Buy |
| Nov-11-24 | Downgrade | Stifel | Buy → Hold |
| Oct-02-24 | Downgrade | BofA Securities | Buy → Neutral |
| Aug-12-24 | Initiated | Piper Sandler | Neutral |
| Jul-09-24 | Initiated | BofA Securities | Buy |
| Jul-09-24 | Initiated | JP Morgan | Overweight |
| Jul-09-24 | Initiated | Longbow | Buy |
| Jul-09-24 | Initiated | Loop Capital | Buy |
| Jul-09-24 | Initiated | Morgan Stanley | Overweight |
| Jul-09-24 | Initiated | Needham | Buy |
| Jul-09-24 | Initiated | Stifel | Buy |
| Jul-09-24 | Initiated | TD Cowen | Buy |
| Jul-09-24 | Initiated | William Blair | Outperform |
View All
Tempus Ai Inc Stock (TEM) Latest News
Form 144 Tempus AI For: 27 September - Investing.com India
Artificial Intelligence Stocks To Watch TodaySeptember 26th - MarketBeat
Tempus AI gets FDA clearance for pulmonary hypertension AI tool - scanx.trade
Tempus AI, Inc. Class A Ignites Investor Hype - TipRanks
Form 144 Tempus AI For: 26 September - Investing.com India
Form 144 Tempus AI For: 26 September By Investing.com - Investing.com Australia
Artificial Intelligence Stocks To Follow TodaySeptember 25th - MarketBeat
Tempus AI, Inc. (TEM) options chain - Yahoo Finance Australia
Tempus AI, Inc. (TEM) Stock Price, News, Quote & History - Yahoo! Finance Canada
Leica Biosystems brings Tempus pathology products to Aperio AI Store, accelerating AI-powered capabilities for oncology research - News-Medical
AI in Clinical Trials Market Set for Transformative Growth Through 2040, Unlocking Opportunities Across Trial Phases, Therapeutic Areas, End Users and Key Global Regions - GlobeNewswire Inc.
#Day 10Looking to Take Profit on my tempus - Moomoo
Tempus AI (NASDAQ:TEM) CEO Sells 250,000 Shares of Company Stock - MarketBeat
RXRX Stock Rises As Tempus AI Deal Resets Growth Story - StocksToTrade
Tempus AI(TEM.US) 10% Shareholder Sells US$19.37 Million in Common Stock - moomoo.com
Tempus AI CEO-linked entities sell 250,000 shares - Stock Titan
Tempus AI Inc Stock (TEM) Closed Up by 7.38% on Sep 24: What Investors Need To Know - TradingKey
Tempus AI (NASDAQ:TEM) Trading 6.1% HigherTime to Buy? - MarketBeat
Tempus AI Soars As Wall Street Bets On Data - TipRanks
Promising Artificial Intelligence Stocks To ConsiderSeptember 24th - MarketBeat
Tempus AI Chief Accounting Officer Sells $529,650 of Stock - The Globe and Mail
Buy 3 AI-Powered Medical Stocks to Strengthen Your Portfolio in Q4 - finance.yahoo.com
Cathie Wood’s ARK sells Tempus AI stock, buys Scribe Therapeutics By Investing.com - Investing.com South Africa
Cathie Wood’s ARK sells Tempus AI stock, buys Scribe Therapeutics - Investing.com
Tempus AI (TEM) Has a $75 Goldman Sachs Target, But Its Data Business Faces a Bigger Test - Yahoo Finance
Tempus AI Stock Price: TEM Stock Chart, Market Cap & News Today - CoinGecko
Tempus AI (NASDAQ:TEM) Upgraded by The Goldman Sachs Group to Hold Rating - MarketBeat
Tempus AI: High Risk, But With A Great Cause (NASDAQ:TEM) - Seeking Alpha
Goldman Sachs initiates coverage of Tempus AI (TEM.US) with a Neutral rating: Diagnostic business to benefit from reimbursement tailwinds, while data contracts enter a "validation phase" - moomoo.com
Tempus AI: Data And Applications Will Unlock More Upside (NASDAQ:TEM) - Seeking Alpha
Tempus AI Sees Pricing, Data Growth Fueling Long-Term Expansion - MarketBeat
Tempus AI Fails to Trim Guardant Lawsuit Over Diagnostic Tests - news.bloomberglaw.com
A data partnership shifts from potential $84 million in two-year fees to $42 million in committed payments over three - Stock Titan
Recursion Pharmaceuticals, Inc. Grants Tempus Ai, Inc. Non-Exclusive License for Rna Foundation Model - marketscreener.com
Tempus AI, Recursion Extend Data License, Amend Fee Structure - moomoo.com
Tempus extends Recursion data partnership through 2029 By Investing.com - Investing.com Nigeria
Tempus AI: Market Is Hyping On An Uncertain Number (NASDAQ:TEM) - Seeking Alpha
Goldman Sachs initiates Tempus AI stock coverage with neutral rating By Investing.com - Investing.com Australia
Goldman Sachs Initiates Tempus AI at Neutral With $75 Price Target - Moomoo
Tempus AI, Inc. (TEM) Stock Analysis: Navigating the Complex Terrain of Healthcare Innovation - DirectorsTalk Interviews
Tempus AI shares rise 5.1% to $70 on Moderna cancer trial validation - scanx.trade
Tempus AI (TEM) Is Building a Heart Failure Agent That Never Sleeps - Yahoo Finance
Tempus AI (TEM), What Is Behind The Latest Buzz? - Yahoo Finance
What Is Tempus AI (TEM)? The $98.5M Mark Behind Q2 - Phemex
Tempus AI CEO Eric P. Lefkofsky sells $16.1 million of stock - Investing.com Nigeria
Tempus AI (TEM) Is Up 31.9% After Launching 100,000‑Genome AI Research Platform Initiative - Yahoo Finance
Tempus AI EVP, Chief Legal Officer Andrew Polovin disposes of 2,951 common shares for $221,325 - Bitget
Tempus AI (TEM) Unveils Whole Genome Platform With Plans For 1 Million Genomes - Yahoo Finance
Tempus AI’s EVP, chief legal officer, sells $221,325 in stock By Investing.com - Investing.com Canada
Tempus AI (TEM) Chief Accounting Officer Ryan Bartolucci Sells 7 - GuruFocus
Tempus AI (NASDAQ:TEM) CAO Sells $529,650.00 in Stock - MarketBeat
Tempus Ai Inc Stock (TEM) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.02%
0.40%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):